Sign inJoin waitlistJoin the waitlist

EN

Eneida Nemecek

Director, Pediatric Bone Marrow Transplant Program, Doernbecher Children’s Hospital · Oregon Health & Science University

Credentials: · · · · ·

History

Oregon Health & Science University
Present
Oregon Health & Science University
Present
Oregon Health & Science University
Present

Oregon Health & Science University
2013
Pediatric Hematology Oncology
University of Washington-Seattle Campus
1999–2002
UH Rainbow Babies & Children’s Ahuja Center for Women & Children
1996–1999
University of Washington
University of Puerto Rico School of Medicine
1992–1996
University of Puerto Rico
1988–1992

Research

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
New England Journal of Medicine · 2018 · 4,577 citations
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Nature Medicine · 2018 · 503 citations
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Journal of Clinical Oncology · 2023 · 326 citations

Michael Pulsipher
18 papers
David Jacobsohn
11 papers
Carrie Kitko
10 papers
Sonali Chaudhury
10 papers
AH
Andrew Harris
9 papers
KK
Kim Kasow
8 papers
Muna Qayed
8 papers
Paul Carpenter
8 papers
Richard Maziarz
8 papers
Stella Davies
8 papers
Stephan Grupp
8 papers
AW
Ann Woolfrey
7 papers

Grants

OHSU Knight Cancer Institute
National Cancer Institute · P30
Project lead · $720K · Oregon Health & Science University
1997–2027
Pbmtc-Aspho 2014: New Frontiers in Pediatric Stem Cell Transplantation
National Heart, Lung, and Blood Institute · R13
Contact PI · $5K · Oregon Health & Science University
2015–2016
Radioimmunotherapy of Acute Leukemia
National Cancer Institute · K23
Contact PI · $668.3K · Oregon Health & Science University
2003–2009
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $3K · University of Washington
2004–2005

Clinical trials

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Principal investigator · Completed · Phase 1, Phase 2
OHSU Knight Cancer Institute
2005–2009
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
Principal investigator · Terminated
OHSU Knight Cancer Institute
2004–2006
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders
Principal investigator · Available
OHSU Knight Cancer Institute
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
Study chair · Completed · Phase 2
Center for International Blood and Marrow Transplant Research
2013–2015